SCHEMBL4169577

SCHEMBL4169577

Cn1c(Nc2ccc(C(C)(C)C)cc2)nc2cc(C(F)(F)F)ccc21

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 12/20 0.54
CYP3A4 P08684 2/20 0.54
RAF1 P04049 4/20 0.52
KDR P35968 5/20 0.51
LCK P06239 2/20 0.48
FYN P06241 2/20 0.48
PDGFRB P09619 2/20 0.48
KIT P10721 2/20 0.48
FLT1 P17948 2/20 0.48
FLT4 P35916 2/20 0.48
STK25 O00506 1/20 0.48
CIT O14578 1/20 0.48
EPHB6 O15197 1/20 0.48
MAP3K7 O43318 1/20 0.48
RIPK2 O43353 1/20 0.48
PAK3 O75914 1/20 0.48
STK10 O94804 1/20 0.48
MAP4K4 O95819 1/20 0.48
ABL1 P00519 1/20 0.48
CSF1R P07333 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12413882 0.88 BRAF (0.50) BRAFCYP3A4RAF1KDRLCK
SCHEMBL12413883 0.86 HDAC6 (0.49) BRAFCYP3A4RAF1KDRLCK
SCHEMBL12412025 0.81 NPC1 (0.49) NPC1RAB9A
SCHEMBL24549210 0.79 ESR1 (0.47) BRAFCYP3A4RAF1KDRLCK
SCHEMBL4981793 0.79 CSNK1D (0.56) BRAFCYP3A4RAF1KDRHDAC6
SCHEMBL12377278 0.78 HSD17B10 (0.52) BRAFRAF1KDRLCKFYN
SCHEMBL3323287 0.76 BRAF (0.57) BRAFRAF1KDRLCKFYN
SCHEMBL6566383 0.75 ALPL (0.41) BRAFCYP3A4RAF1KDR
SCHEMBL19914239 0.74 BRAF (0.41) BRAFCYP3A4RAF1KDRLCK
SCHEMBL21066410 0.74 BRAF (0.41) BRAFCYP3A4RAF1KDRLCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1699453-A4 CYCLIC GUANIDINES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE MERCK & CO INC (US) 2009-07-01 EP disclosed
US-7301036-B2 Cyclic guanidines, compositions containing such compounds and methods of use MERCK & CO., INC. (US) 2007-11-27 US disclosed
US-20070105930-A1 Cyclic guanidines, compositions containing such compounds and methods of use MERCK SHARP & DOHME LLC 2007-05-10 US disclosed
EP-1699453-A1 CYCLIC GUANIDINES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE Merck & Co., Inc. (US) 2006-09-13 EP disclosed
WO-2005065680-A1 CYCLIC GUANIDINES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE MERCK & CO., INC. (US) 2005-07-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105930-A1 Cyclic guanidines, compositions containing such compounds and methods of use GCGR, GLP1R, GCG BRAF 3178/4885CYP3A4 3967/4885RAF1 2011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.